Skip to main content

Table 2 Baseline subject demographic and clinical characteristics

From: Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study

Baseline characteristic

Non-EU (n = 694)

EU (n = 551)

p-value

 

Mean (SD)

Mean (SD)

 

Age (years)

68.0 (6.9)

67.5 (6.2)

0.1994

Height (cm)

159.7 (6.3)

160.1 (6.6)

0.3001

Weight (kg)

65.4 (11.0)

64.7 (9.9)

0.2467

Body mass index (kg/cm2)

25.7 (4.2)

25.2 (3.6)

0.0370*

Caucasian (n, %)

672 (96.8)

543 (98.5)

0.0619

Smoker (Yes) (n, %)

617 (88.9)

421 (76.4)

<0.0001**

Use of alcohol (Yes) (n, %)

556 (80.1)

406 (73.7)

0.0038*

Number of prevalent vertebral fractures (≥1) (n, %)

433 (62.4)

279 (50.6)

<0.0001**

Baseline femoral neck BMD (# of SDs < mean for females)

−2.3 (.6)

−2.2 (.6)

0.0022*

Number of osteoporotic non-vertebral fractures (≥1) (n, %)

366 (52.7)

202 (36.7)

<0.0001**

Family history of osteoporosis (Yes) (n, %)

212 (30.5)

157 (28.5)

0.0001**

History of hysterectomy (Yes) (n, %)

186 (26.8)

134 (24.3)

0.3281

Married (Yes) (n, %)

390 (56.2)

314 (57.0)

0.7732

Number of years postmenopause

20.3 (8.7)

19.4 (7.7)

0.0551

Baseline lumbar spine BMD (# of SDs < mean for females)

−2.4 (1.2)

−2.7 (1.1)

0.0001**

Number of years of education

13.6 (3.1)

10.1 (3.2)

<0.0001**

Number of self-reported preexisting conditions

10.9 (5.9)

5.9 (4.3)

<0.0001**

  1. Abbreviations: BMD Bone mineral density, EU European Union, Non-EU Non-European Union, SD Standard deviation.
  2. *p < 0.05, **p < 0.0001.